Aerovate Therapeutics (AVTE) to Release Quarterly Earnings on Monday

Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) will likely be issuing its Q4 2024 quarterly earnings data before the market opens on Monday, May 12th. Analysts expect Aerovate Therapeutics to post earnings of ($0.30) per share for the quarter.

Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) last issued its quarterly earnings data on Friday, April 25th. The company reported ($3.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($10.50) by $7.35. On average, analysts expect Aerovate Therapeutics to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Aerovate Therapeutics Trading Down 12.3 %

Shares of AVTE stock traded down $1.41 during trading hours on Wednesday, reaching $10.09. 424,316 shares of the company's stock were exchanged, compared to its average volume of 17,982. The company has a market cap of $292.46 million, a price-to-earnings ratio of -3.37 and a beta of 0.95. Aerovate Therapeutics has a fifty-two week low of $43.75 and a fifty-two week high of $884.98. The stock's 50 day moving average is $78.40 and its 200-day moving average is $85.32.

Aerovate Therapeutics Announces Dividend

The firm also recently declared a dividend, which was paid on Monday, April 28th. Investors of record on Friday, April 25th were issued a $84.00 dividend. The ex-dividend date was Tuesday, April 29th.

About Aerovate Therapeutics

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.